Klein Lawrence Otto
Chief Executive Officer
Klein Lawrence Otto has filed 6 SEC Form 4 filings (12 transaction rows) across 1 company, with disclosures dating back to 2026. 6 of those filings fall inside the rolling window. Most recent filing: Oct 2, 2026.
On the most recent filing, Klein Lawrence Otto is listed as Chief Executive Officer at Oruka Therapeutics, Inc. Inside the rolling window, Klein Lawrence Otto reported no open-market purchases and 5 open-market sales totaling $9.4M in ORKA. The largest disclosed transaction in the window is a sale of 75,000 ORKA shares on Sep 1, 2026, worth $6.9M.
Companies traded
Other insiders at ORKA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$9.4M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Klein Lawrence Otto made?
Klein Lawrence Otto has filed 6 SEC Form 4 filings (12 transaction rows) across 1 company since 2026.
Which companies does Klein Lawrence Otto trade?
Klein Lawrence Otto has filed SEC Form 4 disclosures for 1 company, including ORKA.
When was Klein Lawrence Otto's most recent SEC Form 4 filing?
Klein Lawrence Otto's most recent SEC Form 4 filing on Tracefour is dated Oct 2, 2026.
What is Klein Lawrence Otto's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Klein Lawrence Otto is listed as Chief Executive Officer.
What is Klein Lawrence Otto's total buy and sell value in the current window?
Inside the rolling retention window, Klein Lawrence Otto bought $0 and sold $9.4M based on SEC Form 4 filings.
What was Klein Lawrence Otto's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 75,000 ORKA shares on 2026-09-01, worth $6.9M, per SEC Form 4 filings.